Ask AI
ProCE Banner Activity

Evolving Treatment Algorithms in Diffuse Large B-Cell Lymphoma

Clinical Thought

Review this expert commentary outlining how DLBCL care is rapidly evolving as CAR T-cell therapy, bispecific antibodies, and other treatment modalities expand across the treatment continuum.

Released: January 30, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals caring for patients with DLBCL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate emerging evidence for novel treatments for DLBCL and their potential application to clinical practice

  • Educate colleagues and patients on the mechanism of action and clinical rationale for novel agents and combination therapies in DLBCL

  • Select optimal treatments for patients with previously untreated DLBCL, considering expert recommendations along with available efficacy and safety evidence

  • Recommend clinical trials evaluating novel treatments for eligible patients with DLBCL

Disclosure

Primary Author

Laurie H. Sehn, MD, MPH: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Cargo, Chugai, Genmab, Incyte, Janssen, Kite/Gilead, Lilly, Merck, Roche/Genentech, Seagen; researcher (paid to institution): Roche/Genentech.